Evidence map›Paper›PMID 41332325›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

KRAS Withdrawal in Cholangiocarcinoma Leads to Immune Infiltration and Tumor Regression.

Youwei Qiao, Matthew F Yee, Chaitanya N Parikh, Boyang Ma, Yueying Cao, Yu-Huan Shih, Joae Qiong Wu, Marcus Ruscetti, Shun-Qing Liang, Wen Xue

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. KRAS Withdrawal in Cholangiocarcinoma Leads to Immune Infiltration and Tumor Regression.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Youwei QiaoRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, MA, 01605, USA.ORCID https://orcid.org/0000-0002-8495-2097
Matthew F YeeRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, MA, 01605, USA.
Chaitanya N ParikhDepartment of Molecular, Cell and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA, 01605, USA.
Boyang MaDepartment of Molecular, Cell and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA, 01605, USA.
Yueying CaoRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, MA, 01605, USA.
Yu-Huan ShihBiochemistry and Molecular Biotechnology, University of Massachusetts Chan Medical School, Worcester, MA, 01605, USA.
Joae Qiong WuBiochemistry and Molecular Biotechnology, University of Massachusetts Chan Medical School, Worcester, MA, 01605, USA.
Marcus RuscettiDepartment of Molecular, Cell and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA, 01605, USA.
Shun-Qing LiangRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, MA, 01605, USA.
Wen XueRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, MA, 01605, USA.ORCID https://orcid.org/0000-0002-9797-8042

Funding

Vector Immunology CoreP01HL158506 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Terence R. Flotte · 2021 to 2026
$19.5M
Develop combinatorial non-viral and viral CRISPR delivery for lung diseasesUH3HL147367 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI ANDERSON, DANIEL G, GAO, GUANGPING · 2021 to 2022
$2.9M
In vivo prime editing for precision cancer mouse modelsR01CA275945 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Wen Xue · 2023 to 2026
$2.5M
Uncovering the heterogenous role of senescence in prostate immune suppression and tumorigenesisR37CA282805 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Marcus A. Ruscetti · 2024 to 2026
$1.3M
Senescence-Associated Secretory Phenotype (SASP) modulation of the tumor microenvironment as a therapeutic strategy for KRAS-driven tumorsR00CA241110 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI RUSCETTI, MARCUS A. · 2020 to 2022
$747k
Friedreich's Ataxia Research AllianceNCI NIH HHS R00 CA241110NCI NIH HHS R00CA241110NCI NIH HHS R01 CA275945NCI NIH HHS R37 CA282805NCI NIH HHS R37CA282805NHLBI NIH HHS P01 HL158506NHLBI NIH HHS UH3 HL147367NIH HHS P01HL158506NIH HHS R01CA275945NIH HHS R01GM150279NIH HHS UH3HL147367
6 · The paper itself

Abstract

Cholangiocarcinoma (CCA) is a liver cancer subtype with poor survival rates. KRAS mutations are found in 15-40% of CCA, representing a new potential treatment target. Whether KRAS inhibition leads to CCA tumor regression is unknown, partly due to the lack of conditional animal models. A conditional TRE.Kras

Indexed as

Bile Duct NeoplasmsCholangiocarcinomaProto-Oncogene Proteins p21(ras)AnimalsDisease Models, AnimalHumansMiceMice, KnockoutHras protein, mouseProto-Oncogene Proteins p21(ras)biliary malignancycholangiocarcinomaKRAS inhibitiononcology

Identifiers

PMID41332325
PMCPMC12866855

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.